Names
Evomela™ Melphalan hydrochlorideIndications and usage
U.S. Food and Drug Administration (FDA) has granted approval of EVOMELA for use in two indications:
- Use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation (ASCT) in patients with multiple myeloma (MM)
- For the palliative treatment of patients with MM for whom oral therapy is not appropriate.
This is the first product to be FDA-approved for the high-dose conditioning indication in MM.
Side effects needing medical attention
Low neutrophil count, low white blood cell count, low lymphocyte count, low platelet count, diarrhea, nausea, fatigue, low potassium in the blood, anemia, and vomiting.